Yang Y, Liang W, Fan K, Yang T, Cheng J
Front Endocrinol (Lausanne). 2024; 15:1440247.
PMID: 39544231
PMC: 11560426.
DOI: 10.3389/fendo.2024.1440247.
Zhang X, Chen Y, Yu Y, Li J
Int J Endocrinol. 2024; 2024:5085905.
PMID: 39224564
PMC: 11368557.
DOI: 10.1155/2024/5085905.
Dzialach L, Sobolewska J, Zak Z, Respondek W, Witek P
Front Endocrinol (Lausanne). 2024; 15:1338345.
PMID: 38370355
PMC: 10870150.
DOI: 10.3389/fendo.2024.1338345.
Burman P, Casar-Borota O, Perez-Rivas L, Dekkers O
J Clin Endocrinol Metab. 2023; 108(7):1585-1601.
PMID: 36856733
PMC: 10271233.
DOI: 10.1210/clinem/dgad098.
Yang Z, Tian X, Yao K, Yang Y, Zhang L, Liu N
Brain Sci. 2023; 13(2).
PMID: 36831707
PMC: 9954754.
DOI: 10.3390/brainsci13020164.
Treatment of Prolactinoma.
Inder W, Jang C
Medicina (Kaunas). 2022; 58(8).
PMID: 36013562
PMC: 9413135.
DOI: 10.3390/medicina58081095.
Identification and Verification of SLC27A1, PTBP1 and EIF5A With Significantly Altered Expression in Aggressive Pituitary Adenomas.
Cheng J, Sun R, Nie D, Li B, Gui S, Li C
Front Surg. 2022; 9:923143.
PMID: 35836612
PMC: 9275011.
DOI: 10.3389/fsurg.2022.923143.
Delayed Craniospinal Metastasis of Aggressive Nonfunctioning Pituitary Adenomas as Pituitary Carcinomas.
Raghu A, Everson M, Helal A, Kiyofuji S, Clarke M, Link M
J Neurol Surg B Skull Base. 2022; 83(Suppl 2):e253-e259.
PMID: 35832993
PMC: 9272318.
DOI: 10.1055/s-0041-1725024.
Temozolomide and Capecitabine Treatment for an Aggressive Somatotroph Pituitary Tumor: A Case Report and Literature Review.
Ishida A, Shichi H, Fukuoka H, Shiramizu H, Inoshita N, Yamada S
Front Oncol. 2022; 12:916982.
PMID: 35712496
PMC: 9197190.
DOI: 10.3389/fonc.2022.916982.
Tamoxifen Exerts Anticancer Effects on Pituitary Adenoma Progression via Inducing Cell Apoptosis and Inhibiting Cell Migration.
Lv T, Zhang Z, Yu H, Ren S, Wang J, Li S
Int J Mol Sci. 2022; 23(5).
PMID: 35269804
PMC: 8910631.
DOI: 10.3390/ijms23052664.
Pituitary Carcinoma in a Patient with Cowden Syndrome.
Zhang H, Li J, Lee M, Ho C
Am J Case Rep. 2022; 23:e934846.
PMID: 35110519
PMC: 8822848.
DOI: 10.12659/AJCR.934846.
Temozolomide Nonresponsiveness in Aggressive Prolactinomas and Carcinomas: Management and Outcomes.
Das L, Rai A, Salunke P, Ahuja C, Sood A, Radotra B
J Endocr Soc. 2022; 6(2):bvab190.
PMID: 35059545
PMC: 8763612.
DOI: 10.1210/jendso/bvab190.
Early Initiation of Temozolomide Therapy May Improve Response in Aggressive Pituitary Adenomas.
Das L, Gupta N, Dutta P, Walia R, Vaiphei K, Rai A
Front Endocrinol (Lausanne). 2022; 12:774686.
PMID: 34975752
PMC: 8718901.
DOI: 10.3389/fendo.2021.774686.
Diagnosis and treatment of refractory pituitary adenomas: a narrative review.
Liu X, Dai C, Feng M, Li M, Chen G, Wang R
Gland Surg. 2021; 10(4):1499-1507.
PMID: 33968701
PMC: 8102214.
DOI: 10.21037/gs-20-873.
Multimodal Non-Surgical Treatments of Aggressive Pituitary Tumors.
Nakano-Tateno T, Lau K, Wang J, McMahon C, Kawakami Y, Tateno T
Front Endocrinol (Lausanne). 2021; 12:624686.
PMID: 33841328
PMC: 8033019.
DOI: 10.3389/fendo.2021.624686.
Case Report: Temozolomide Treatment of Refractory Prolactinoma Resistant to Dopamine Agonists.
Tang H, Cheng Y, Huang J, Li J, Zhang B, Wu Z
Front Endocrinol (Lausanne). 2021; 12:616339.
PMID: 33776913
PMC: 7996095.
DOI: 10.3389/fendo.2021.616339.
Characteristic of Tumor Regrowth After Gamma Knife Radiosurgery and Outcomes of Repeat Gamma Knife Radiosurgery in Nonfunctioning Pituitary Adenomas.
Li Y, Wu L, Quan T, Fu J, Cao L, Li X
Front Oncol. 2021; 11:627428.
PMID: 33763363
PMC: 7982800.
DOI: 10.3389/fonc.2021.627428.
Aggressive prolactinomas: how to manage?.
Lasolle H, Ilie M, Raverot G
Pituitary. 2019; 23(1):70-77.
PMID: 31617128
DOI: 10.1007/s11102-019-01000-7.
MGMT immunohistochemistry in pituitary tumors: controversies with clinical implications.
Kontogeorgos G, Thodou E, Koutourousiou M, Kaltsas G, Seretis A
Pituitary. 2019; 22(6):614-619.
PMID: 31571099
DOI: 10.1007/s11102-019-00993-5.
Temozolomide therapy for aggressive functioning pituitary adenomas refractory to surgery and radiation: a case series.
Jordan J, Miller J, Cushing T, Seijo M, Batchelor T, Arrillaga-Romany I
Neurooncol Pract. 2019; 5(1):64-68.
PMID: 31385986
PMC: 6655410.
DOI: 10.1093/nop/npx013.
